Lupin joins hands with DST

Our News Bureau - Mumbai

Lupin and the Department of Science and Technology (DST), Government of India have joined hands for the clinical development of Lupin's migraine and psoriasis projects. After an exhaustive review and evaluation of the proposals received from the industry, the DST has selected two clinical development programmes for funding, both of Lupin in the disease area of migraine and psoriasis. The migraine project involves conducting of Phase III clinical trials of Lupin's LL-2011 (Amigra, a herbal formulation being developed as a nasal spray) for prophylactic treatment of migraine. As against this, the collaboration on psoriasis will support the extended Phase I and Phase II trials of LL-4218, a pure compound derived from a herbal source, for the treatment of chronic stable plaque type of psoriasis. The DST has committed over Rs 10 crore to support Lupin's clinical development projects, which are expected to be completed in two years. Speaking of the collaboration, Dr D B Gupta, Chairman, Lupin, reiterated the company's commitment to support the discovery and development of new drugs for human healthcare and greatly appreciated the support extended by the Government of India in the clinical development of Lupin's anti-migraine and anti-psoriasis agents.